Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* subjects who had successfully completed the previous Dose Finding Study and were fully compliant to the inclusion/exclusion criteria described in the previous DSC/08/2357/36~Exclusion Criteria:~* patients with fever related to JIA or other systemic features of JIA during 12 months before entering the study~* active bacterial or mycotic infection requiring antimicrobial treatment~* episode of macrophage activation syndrome over the last 6 months~* baseline prolongation of QT/QTc interval, use of concomitant medications that prolong the QT/QTc interval or history of additional risk factors for TdP.~* clinically significant cardiovascular disease~* clinically significant illness i.e. any condition that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study~* psychiatric illness/social situation that would limit compliance with study medication and protocol requirements~* inherited metabolic diseases~* presence of malignancy~* pregnancy or lactation~* positive blood test for HIV~* active EBV infection, active B and/or C hepatitis~* platelet count \<100x10(9)/L

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Givinostat (Type: EXPERIMENTAL): Patient received the dose of 0.75 mg/kg BID from December 28th, 2011 to January 27th, 2014

Based on this trial design, predict the completion outcome and termination type (if applicable).